Stockreport

BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting

BeyondSpring, Inc. - Ordinary Shares  (BYSI) 
Last beyondspring, inc. - ordinary shares earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.beyondspringpharma.com
PDF NEW YORK, May 16, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapi [Read more]